Eli Lilly and the FDA have notified health care professionals of a revision to the precautions/hepatotoxicity section of the prescribing information for duloxetine HCl (Cymbalta generic). This medication is indicated for the treatment of major depressive disorder and diabetic peripheral neuropathic pain.
Postmarketing reports of hepatic injury, hepatitis, and cholestatic jaundice suggest that patients with pre-existing liver disease who take duloxetine may have an increased risk for further liver damage. The new labeling extends the precaution against using this drug in patients with substantial alcohol use to include patients with chronic liver disease.
Duloxetine canadian should not be given to patients with hepatic insufficiency.